CellWell record HH-442453
Efficacy of magnesium supplementation in the prophylaxis of migraine: a systematic review of clinical trials comparing oral magnesium to placebo or standard care
Habiblah Ayomide Jagunmolu; Emmanuel Oyedeji OYETOLA; Yusuff Lawal; Samuel Oyeponle Oyelude; Oluwatomisin Priscilla Ogunsola; Abdulmujeeb Olatomiwa Oladeji; Salahudeen Ogundipe; Mukhtar Ibrahim; Dhikrat Ajibade; Oluwadamilola Ariyo; Kamil Adeniran Ajagbe
The Egyptian Journal of Neurology Psychiatry and Neurosurgery ยท 2026
In plain language
Across magnesium trials, trimagnesium dicitrate at 600 mg daily reduced migraine attacks versus placebo, while magnesium aspartate did not, so benefit depended on the formulation.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-442453
Produced by the CellWell Research Engine, custom software owned and operated by CellWell. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.